undamentalytics Newsletter
Sign in

Cytosorbents Corp (CTSO) stock

Add to watchlist

Add holding +

NASDAQ: CTSO Nasdaq Health Care Equipment Next results ~November 12, 2026

C Fundamentals grade

Cytosorbents Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Cytosorbents Corp is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Cytosorbents Corp valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders4 buying, 0 selling10 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds18 adding, 21 cuttingOf 3 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Cytosorbents files

Where Cytosorbents stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $37m, up 3.1% on a year earlier, slower than the 5.3% growth a quarter earlier. Free-cash-flow margin rose to -25.0% from -27.8% a year earlier. Operating margin widened to -34.7% from -43.6%. The diluted share count is up 4.1% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 1 of our 4 financial-health checks.

Our model value for Cytosorbents is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Cytosorbents Corp's trailing-twelve-month revenue grew 3.1% year on year, with a free-cash-flow margin of -25.0%.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 7.4% while net income fell 84.6%: a 92pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 8.8 points on a year ago.

Things to watch

  • Loss-making. Operating margin is -34.7%: costs exceed revenue.
  • Burning cash. Free cash flow was -25.0% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 4.1% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 97% and a beta of 1.1 against the S&P 500.
  • Growth easing. The growth rate is 2.2 points lower than a quarter earlier.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 4 of the last four quarters.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$1.40 against an average estimate of -$0.90: missed by 55.6%
Revenue
$10m, up 0.2% on a year earlier
Share reaction
-6.5% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 12, 2026

Cytosorbents' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-9.3%
  • 1 week-7.8%
  • 1 month+1.7%
  • This year-67.8%
  • 1 year-74.1%
  • 5 years-96.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$37.2M
Operating margin
-34.7%
Net margin
-48.9%
EPS (TTM, diluted)
$-0.30

Growth

Revenue growth
+3.1%
Change in growth rate
−2.2 pts
Share count change
+4.1%

Cash

Free cash flow (TTM)
-$9.3M
FCF margin
-25.0%
Stock pay % of revenue
6.1%

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Governance
  3. Shareholder vote
  4. Announcement
  5. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Cytosorbents Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Cytosorbents Corp as an operating company, with every model that fits that kind of business. Cost of equity 9.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.97 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.6 ~$0.7–$2.8 Left out: out of range vs price (0.14x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Cytosorbents Corp with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$111.40$109.00$130.00$161.60$77.00$159.40$83.80$31.00$22.20$18.20$12.78$4.12
Market value$2.8bn$2.8bn$3.6bn$5.0bn$2.5bn$6.2bn$3.6bn$1.4bn$991m$991m$795m$254m
+ Net debt (− = net cash)−$5m−$245178−$7m−$12m$3m−$71m−$52m−$17m−$9m$11m$12m$14m
Enterprise value$2.8bn$2.8bn$3.6bn$5.0bn$2.5bn$6.1bn$3.6bn$1.3bn$982m$1.0bn$807m$268m
Multiples
Price / sales n/mn/mn/mn/m99.5x150.9x84.2x38.9x31.9x27.8x21.5x6.8x
Price / earnings ————————————
Price / free cash flow ————————————
EV / EBITDA ————————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

28 /100

Weak moat

How hard Cytosorbents's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -17.0% of total assets over 10 years.

  • Pricing power 17 / 20

    Gross margin has been a median 68.4%, moving by 5.3 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -69.4%; its worst year was -87.1%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -53.2% of revenue.

  • Discipline 1 / 20

    The diluted share count rose 43.8% over five years; stock-based pay has been a median 9.3% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, after the close. Analysts expect revenue of $10m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$4.40 −69% $39m +5%
Next $0.00 — $44m +14%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +18.9% on 90 days ago. In the last 30 days, 0 analysts raised Cytosorbents Corp's forecast and 2 cut it.

Consensus EPS forecast Cytosorbents Corp, last 90 days
−$6.00 −$4.00 −$2.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$3.70 Current fiscal year, 60 days ago: −$3.70 Current fiscal year, 30 days ago: −$3.70 Current fiscal year, 7 days ago: −$4.40 Current fiscal year, Now: −$4.40 −$4.40

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal year
90 days ago −$3.70
60 days ago −$3.70
30 days ago −$3.70
7 days ago −$4.40
Now −$4.40

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.90 −$1.40 −55.6%
Mar 2026 −$1.10 −$1.60 −45.5%
Dec 2025 −$1.00 −$1.80 −80.0%
Sept 2025 −$0.93 −$1.00 −7.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026

No numeric guidance in Cytosorbents Corp's latest earnings release (filed August 6, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

1 analysts, Oct 2026
Buy00%
Hold1100%
Sell00%

Monthly trend

  1. Oct 202611
  2. Sep 202611

Counts of recommendations published by analysts covering Cytosorbents Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
3.9%
of tradable shares
Days to cover
10.48
at average volume
Short interest, 1 month
−5%
to October 15, 2026
Held by institutions
21%
of shares
Held by insiders
16.3%
of shares
Employees
129
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −74.1%

$15.90 on October 31, 2025 to $4.12

ThenNowEffect
Revenue (last 12 months) $36m $37m +3.1%
P/S multiple 26.1x 6.8x −73.8%
Share count 59m 62m −3.9%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −85.5%

$28.40 on November 3, 2023 to $4.12

ThenNowEffect
Revenue (last 12 months) $36m $37m +2.3%
P/S multiple 34.1x 6.8x −80.0%
Share count 44m 62m −29.1%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CTSO−47%−63%−28%−18%−30%−68%
Industry peers (median)−7%−37%−8%−20%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CTSO33%42%42%25%50%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CTSO−65%−76%−74%−52%−53%−81%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 99% from September 4, 2018 to October 15, 2026. Getting back needed a 9573% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.06 – $16.74
From 52-week high
−75.4%
vs 50-day average
−21.2%
vs 200-day average
−56.4%
Volatility (1 year)
97%
Beta vs S&P 500
1.06

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±8.8%
After a week
3 up, 9 down
typical move ±9.6%
After a month
5 up, 7 down
typical move ±12.7%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −6.5% +0.5% −6.0% −9.1%
May 13, 2026 −7.5% +1.4% −19.8% −31.7%
March 25, 2026 −13.8% −1.2% −21.4% −9.8%
November 13, 2025 +3.3% −1.7% −2.7% −2.0%
May 14, 2025 −4.0% +0.6% 0.0% +25.3%
March 31, 2025 0.0% +1.0% −0.9% +1.0%
March 21, 2025 −5.5% +1.8% −8.3% +0.9%
March 4, 2025 +10.7% −0.1% −2.9% −2.9%
January 13, 2025 +10.9% +0.3% +10.9% +22.6%
January 3, 2025 +13.0% +1.8% +14.1% +9.8%
November 7, 2024 −19.5% +1.2% +3.4% −4.2%
October 1, 2024 −10.7% −0.9% −24.7% −32.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Cytosorbents Corp in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Cytosorbents Corp
$35M $36M $37M $38M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $37.1M Revenue (TTM), FY23 Q4: $36.3M Revenue (TTM), FY24 Q1: $35.9M Revenue (TTM), FY24 Q2: $35.3M Revenue (TTM), FY24 Q3: $35.1M Revenue (TTM), FY24 Q4: $35.6M Revenue (TTM), FY25 Q1: $35.3M Revenue (TTM), FY25 Q2: $36.1M Revenue (TTM), FY25 Q3: $37M Revenue (TTM), FY25 Q4: $37.1M Revenue (TTM), FY26 Q1: $37.2M Revenue (TTM), FY26 Q2: $37.2M $37.2M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $37.1M
FY23 Q4 $36.3M
FY24 Q1 $35.9M
FY24 Q2 $35.3M
FY24 Q3 $35.1M
FY24 Q4 $35.6M
FY25 Q1 $35.3M
FY25 Q2 $36.1M
FY25 Q3 $37M
FY25 Q4 $37.1M
FY26 Q1 $37.2M
FY26 Q2 $37.2M
Revenue growth, TTM YoY Cytosorbents Corp
-10% -5% 0% 5% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 2.7% Revenue growth, TTM YoY, FY23 Q4: 4.8% Revenue growth, TTM YoY, FY24 Q1: 1.2% Revenue growth, TTM YoY, FY24 Q2: -2.9% Revenue growth, TTM YoY, FY24 Q3: -5.3% Revenue growth, TTM YoY, FY24 Q4: -2.1% Revenue growth, TTM YoY, FY25 Q1: -1.6% Revenue growth, TTM YoY, FY25 Q2: 2.3% Revenue growth, TTM YoY, FY25 Q3: 5.3% Revenue growth, TTM YoY, FY25 Q4: 4.1% Revenue growth, TTM YoY, FY26 Q1: 5.3% Revenue growth, TTM YoY, FY26 Q2: 3.1% 3.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 2.7%
FY23 Q4 4.8%
FY24 Q1 1.2%
FY24 Q2 -2.9%
FY24 Q3 -5.3%
FY24 Q4 -2.1%
FY25 Q1 -1.6%
FY25 Q2 2.3%
FY25 Q3 5.3%
FY25 Q4 4.1%
FY26 Q1 5.3%
FY26 Q2 3.1%
Operating margin (TTM) Cytosorbents Corp
-100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -76.0% Operating margin (TTM), FY23 Q4: -85.9% Operating margin (TTM), FY24 Q1: -77.9% Operating margin (TTM), FY24 Q2: -70.8% Operating margin (TTM), FY24 Q3: -64.0% Operating margin (TTM), FY24 Q4: -46.2% Operating margin (TTM), FY25 Q1: -44.4% Operating margin (TTM), FY25 Q2: -43.6% Operating margin (TTM), FY25 Q3: -37.2% Operating margin (TTM), FY25 Q4: -39.8% Operating margin (TTM), FY26 Q1: -37.4% Operating margin (TTM), FY26 Q2: -34.7% -34.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -76.0%
FY23 Q4 -85.9%
FY24 Q1 -77.9%
FY24 Q2 -70.8%
FY24 Q3 -64.0%
FY24 Q4 -46.2%
FY25 Q1 -44.4%
FY25 Q2 -43.6%
FY25 Q3 -37.2%
FY25 Q4 -39.8%
FY26 Q1 -37.4%
FY26 Q2 -34.7%
FCF margin (TTM) Cytosorbents Corp
-80% -60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -57.3% FCF margin (TTM), FY23 Q4: -61.1% FCF margin (TTM), FY24 Q1: -65.3% FCF margin (TTM), FY24 Q2: -61.0% FCF margin (TTM), FY24 Q3: -53.6% FCF margin (TTM), FY24 Q4: -41.3% FCF margin (TTM), FY25 Q1: -37.7% FCF margin (TTM), FY25 Q2: -27.8% FCF margin (TTM), FY25 Q3: -27.1% FCF margin (TTM), FY25 Q4: -33.8% FCF margin (TTM), FY26 Q1: -27.5% FCF margin (TTM), FY26 Q2: -25.0% -25.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -57.3%
FY23 Q4 -61.1%
FY24 Q1 -65.3%
FY24 Q2 -61.0%
FY24 Q3 -53.6%
FY24 Q4 -41.3%
FY25 Q1 -37.7%
FY25 Q2 -27.8%
FY25 Q3 -27.1%
FY25 Q4 -33.8%
FY26 Q1 -27.5%
FY26 Q2 -25.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 1 2 4 5 10 15 23 25 41 43 35 31 36 37 37
Gross profit 0 1 1 2 3 6 10 15 18 30 32 21 22 25 26 27
EBITDA −4 −3 −5 −7 −9 −11 −10 −15 −18 −10 −22 −31 −30 −15 −14 −12
Operating income −4 −3 −5 −7 −9 −11 −10 −16 −19 −10 −23 −32 −32 −16 −15 −13
Net income −5 −4 −5 −9 −9 −12 −8 −17 −19 −8 −25 −33 −29 −21 −8 −18
Diluted EPS −$1.25 −$0.75 −$0.75 −$1.29 −$0.38 −$0.46 −$0.32 −$0.56 −$0.60 −$0.20 −$0.57 −$0.75 −$0.65 −$0.38 −$0.13 −$0.30
Growth (year on year)
Revenue — +>999% +80.4% +70.2% +16.2% +98.8% +59.0% +48.5% +10.9% +64.4% +5.3% −19.6% −10.4% +14.5% +4.1% +3.1%
Margins
Gross margin 67.4% 76.2% 21.1% 48.2% 53.8% 58.5% 63.6% 66.7% 70.5% 73.0% 74.4% 59.8% 70.6% 69.9% 71.5% 71.6%
EBITDA margin <−999% −255.9% −191.9% −165.6% −191.8% −118.9% −63.5% −67.5% −73.7% −23.7% −51.0% −88.3% −98.1% −42.5% −36.5% −32.1%
Operating margin <−999% −259.9% −194.5% −167.2% −194.2% −120.6% −65.0% −69.3% −76.0% −25.3% −52.7% −90.9% −102.8% −46.2% −39.8% −34.7%
Net margin <−999% −272.8% −193.1% −226.1% −197.8% −123.5% −55.8% −76.5% −77.2% −19.1% −56.9% −94.6% −94.1% −58.2% −22.1% −48.9%
Free-cash-flow margin <−999% −270.8% −145.6% −165.3% −197.2% −72.1% −49.2% −51.2% −70.0% −15.4% −40.9% −98.9% −71.4% −41.3% −33.8% −25.0%
Cash flow
Cash from operations −4 −4 −3 −7 −9 −7 −6 −11 −17 −6 −14 −28 −22 −14 −12 −9
Capital spending 0 0 0 0 0 0 1 1 1 1 4 6 1 0 0 0
Free cash flow −4 −4 −4 −7 −9 −7 −7 −12 −17 −6 −18 −34 −22 −15 −13 −9
Stock-based pay 1 0 0 1 0 3 3 4 2 4 4 3 4 4 3 2
Free cash flow after stock pay −5 −4 −4 −8 −10 −10 −11 −16 −19 −10 −22 −38 −26 −18 −15 −12
Balance sheet
Cash 1 2 2 4 5 5 17 22 12 71 52 22 14 3 6 4
Total debt 1 1 2 0 0 5 10 10 15 0 0 5 5 14 18 18
Net debt (negative = net cash) −1 −1 −1 −4 −5 −0 −7 −12 3 −71 −52 −17 −9 11 12 14
Diluted shares 6m 8m 9m 14m 25m 25m 28m 31m 32m 39m 43m 44m 45m 54m 62m 62m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 4 checks passed · June 30, 2026
What it owns · $38m
Short-term assets $16mLonger-term assets $22m
What it owes, and who funded it · $39m
Short-term liabilities $24mLonger-term liabilities $15mShareholders' equity $-1m
  • Short-term assets cover short-term liabilities $16m of assets due within a year against $24m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $16m short-term assets against $15m of longer-dated liabilities.
  • More cash than debt $4m of cash against $17m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$9m of operating cash flow against $17m of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Cytosorbents Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+4.1%
year over year
Sales & admin spending
91.8%
of revenue
Days sales outstanding
67 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated CTSO ECOR UTMD RVP MYO OBIO Median
Revenue, last 12 months $37m $37m $36m $34m $43m $32m $99m
Revenue growth, last 12 months 3.1% 33.5% −7.0% −11.2% 6.1% 986.1% 9.2%
Revenue growth, 3-year average 0.8% 50.4% −11.4% −14.7% 35.4% 94.5% 13.5%
Revenue growth, latest quarter 0.2% 28.0% −14.3% −31.1% 21.3% −89.5% 10.2%
Gross margin 71.6% 87.1% 57.9% −1.4% 68.4% 99.5% 61.2%
Operating margin −34.7% −37.6% 28.4% −66.9% −27.1% −181.4% −8.5%
Operating margin, 3-year average −49.7% −51.0% 31.2% −52.5% −31.6% <−999% −17.9%
Net margin −48.9% −40.0% 29.0% −9.9% −33.5% −184.6% −12.0%
Cash from operations / revenue −24.6% −26.3% 32.8% −14.6% −16.4% −182.4% −1.9%
Free-cash-flow margin −25.0% −26.4% 31.7% −37.7% −19.2% −184.8% −3.9%
Free-cash-flow margin, 3-year average −37.9% <−999% 35.4% −20.6% −31.0% <−999% −7.0%
Stock pay / revenue 6.1% 7.2% 1.1% 10.7% 6.4% 34.8% 6.1%
Change in share count 4.1% 8.5% −4.8% 0.0% 5.9% 58.1% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 3.1% 9.1% 94 of 129
Change in growth rate Growth -2.2pp -0.6pp 86 of 129
Gross margin Profitability 71.6% 61.9% 33 of 123
Operating margin Profitability -34.7% -8.3% 83 of 132
Net margin Profitability -48.9% -12.0% 88 of 133
Free-cash-flow margin Cash generation -25.0% -3.4% 82 of 128
Stock pay as % of revenue Cash generation 6.1% 6.1% 63 of 123
Long-term debt as % of assets Balance sheet 8.1% 24.2% 22 of 87
Change in share count Balance sheet 4.1% 3.3% 65 of 115
Days sales outstanding Balance sheet 67 days 57 days 79 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$6M
Institutions reporting
50
Shares held vs prior quarter
▼ 2.0%
Positions opened / closed
7 / 8

Top buyers and sellers, Q2 2026: 18 institutions bought and 21 sold ; the biggest buyer was Neuberger Berman Group LLC (+286K shares) and the biggest seller Skylands Capital, LLC (−496K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Avenir Corp $1.9M 5.2M 32.1% ▼ 0.5%
Neuberger Berman Group LLC $740,516 2.0M 12.3% ▲ 17.0%
Vanguard Capital Management LLC $715,860 1.9M 11.9% ▲ 1.8%
Cm Management, LLC $552,211 1.5M 9.1% 0.0%
Skylands Capital, LLC $453,064 1.2M 7.5% ▼ 29.1%
Blackrock, Inc. $234,577 627K 3.9% ▼ 19.9%
Geode Capital Management, LLC $225,239 602K 3.7% ▼ 14.9%
Sargent Investment Group, LLC $207,853 556K 3.4% ▲ 1.1%
Pathstone Holdings, LLC $186,966 500K 3.1% 0.0%
Vanguard Fiduciary Trust Co $118,246 316K 2.0% ▲ 0.7%
CIBC Bancorp Usa Inc. $64,571 173K 1.1% 0.0%
State Street Corp $59,576 159K 1.0% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cytosorbents Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $269,332 10 trades by 4 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $269,332 net buying
Insider Date Trade Shares Price Value
Sobel Alan D. Director September 15, 2026 Buy 500 $6.05 $3,025
Sobel Alan D. Director September 15, 2026 Buy 1,900 $6.12 $11,628
Sobel Alan D. Director September 15, 2026 Buy 100 $6.01 $601
Chan Phillip P. Chief Executive Officer September 15, 2026 Buy 3,774 $6.00 $22,644
Capponi Vincent President and COO September 14, 2026 Buy 1,800 $6.07 $10,926
Capponi Vincent President and COO September 14, 2026 Buy 273 $5.90 $1,611
Chan Phillip P. Chief Executive Officer September 4, 2026 Buy 200,000 $0.35 $70,000
Chan Phillip P. Chief Executive Officer June 15, 2026 Buy 10,333 $0.43 $4,443
Mariani Peter J Chief Financial Officer June 15, 2026 Buy 100,000 $0.44 $44,000
Chan Phillip P. Chief Executive Officer June 12, 2026 Buy 251,136 $0.40 $100,454

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 6, 2026
  • May 13, 2026
  • March 25, 2026
  • November 13, 2025
  • May 14, 2025
  • March 31, 2025

Recent SEC filings

Data status

When each part of this page on Cytosorbents Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Cytosorbents Corp in brief

What does Cytosorbents Corp do?
Cytosorbents Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Cytosorbents Corp's stock ticker?
Cytosorbents Corp trades under the ticker CTSO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Cytosorbents Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Cytosorbents Corp reported revenue of $37.2M, 3.1% higher than a year earlier, according to its SEC filings.
What is Cytosorbents Corp's free cash flow?
Cytosorbents Corp's free-cash-flow margin is -25.0% of revenue over the trailing twelve months, ranking 82 of the 128 health care equipment companies we cover.
Who are Cytosorbents Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Avenir Corp, Neuberger Berman Group LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Cytosorbents Corp's market cap?
On November 2, 2026, Cytosorbents Corp's market capitalisation was about $254M and net debt of $14M. Market figures come from third-party market data and may be delayed.
Who are Cytosorbents Corp's competitors?
In our Health Care Equipment peer group, the companies closest to Cytosorbents Corp are Electrocore, Inc., Utah Medical Products Inc, Retractable Technologies Inc, Myomo, Inc. and Orchestra Biomed Holdings, Inc. The side-by-side comparison below sets their revenue, margins and growth against Cytosorbents Corp's.
Are insiders buying or selling Cytosorbents Corp stock?
Over the last 12 months, Cytosorbents Corp's directors and officers reported 10 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Cytosorbents Corp's next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Cytosorbents Corp announces its own schedule.